Literature DB >> 30578256

How I treat low von Willebrand factor levels.

Michelle Lavin1, James S O'Donnell1.   

Abstract

Partial quantitative deficiency of plasma von Willebrand factor (VWF) is responsible for the majority of cases of von Willebrand disease (VWD), the most common inherited human bleeding disorder. International consensus guidelines recommend that patients with reduced plasma VWF antigen (VWF:Ag) levels and bleeding phenotypes be considered in 2 distinct subsets. First, patients with marked reductions in plasma VWF levels (<30 IU/dL) usually have significant bleeding phenotypes and should be classified with "type 1 VWD." In contrast, patients with intermediate reduced plasma VWF levels (in the range of 30-50 IU/dL) should be considered in a separate category labeled "low VWF levels." These patients with low VWF commonly display variable bleeding phenotypes and often do not have VWF gene sequence variations. Because the pathophysiology underlying low VWF levels remains largely undefined, diagnosis and management of these patients continue to pose significant difficulties. In this article, we present a number of clinical case studies to highlight these common clinical challenges. In addition, we detail our approach to establishing a diagnosis in low VWF patients and discuss strategies for the management of these patients in the context of elective surgery and pregnancy.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30578256     DOI: 10.1182/blood-2018-10-844936

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

Review 2.  Low VWF: insights into pathogenesis, diagnosis, and clinical management.

Authors:  James S O'Donnell
Journal:  Blood Adv       Date:  2020-07-14

3.  The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding.

Authors:  Lakshmi Srivaths; Charles G Minard; Sarah H O'Brien; Allison P Wheeler; Eric Mullins; Mukta Sharma; Robert Sidonio; Shilpa Jain; Ayesha Zia; Margaret V Ragni; Roshni Kulkarni; Jennifer E Dietrich; Peter A Kouides
Journal:  Blood Adv       Date:  2020-07-14

4.  Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.

Authors:  Chatphatai Moonla; Benjaporn Akkawat; Yaowaree Kittikalayawong; Autcharaporn Sukperm; Mukmanee Meesanun; Noppacharn Uaprasert; Darintr Sosothikul; Ponlapat Rojnuckarin
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

5.  Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding.

Authors:  Ferdows Atiq; Esmee Wuijster; Moniek P M de Maat; Marieke J H A Kruip; Marjon H Cnossen; Frank W G Leebeek
Journal:  J Thromb Haemost       Date:  2021-01-24       Impact factor: 5.824

Review 6.  Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Blood Med       Date:  2021-03-22

7.  The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial.

Authors:  Katarina D Kovacevic; Jürgen Grafeneder; Christian Schörgenhofer; Georg Gelbenegger; Gloria Gager; Christa Firbas; Peter Quehenberger; Petra Jilma-Stohlawetz; Andrea Bileck; Shuhao Zhu; James C Gilbert; Martin Beliveau; Bernd Jilma; Ulla Derhaschnig
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.